deferasirox has been researched along with Disease Models, Animal in 24 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (16.67) | 29.6817 |
| 2010's | 14 (58.33) | 24.3611 |
| 2020's | 6 (25.00) | 2.80 |
| Authors | Studies |
|---|---|
| Abrams, RPM; Bachani, M; Balasubramanian, A; Brimacombe, K; Dorjsuren, D; Eastman, RT; Hall, MD; Jadhav, A; Lee, MH; Li, W; Malik, N; Nath, A; Padmanabhan, R; Simeonov, A; Steiner, JP; Teramoto, T; Yasgar, A; Zakharov, AV | 1 |
| Baum, L; Ho, A; Kwan, P | 1 |
| Chunyu, W; Gao, X; Liu, S; Peng, M; Ran, L; Sun, L; Wan, J; Wang, Y; Wu, Y; Yang, K; Yang, Y; Yin, M | 1 |
| Hara, H; Imai, T; Matsubara, H; Nakamura, S; Ohba, T; Shimazawa, M; Sugiyama, T; Tsuji, S | 1 |
| Gouda, T; Hara, H; Imai, T; Nakamura, S; Nishimura, Y; Saito, Y; Shimazawa, M | 1 |
| Drevet, JR; Eskandari, A; Gharagozloo, P; Hosseini, M; Nasr-Esfahani, MH; Nazem, MN; Rahmani, M; Sadeghi, N; Shaygannia, E; Tavalaee, M | 1 |
| Shen, JC; Zhang, YC; Zhao, MF | 1 |
| Hu, H; Liu, W; Wen, X; Wu, D; Ye, B; Zhou, Y | 1 |
| Laws, JL; McTigue, DM; Sauerbeck, A; Schonberg, DL | 1 |
| Amanlou, M; Arabzadeh, AJ; Ardestani, MS; Delbaz, SA; Ebrahimi, SE; Javidi, A; Mahian, H; Rad, AM | 1 |
| Balooch, FD; Fatemi, SJ; Golbafan, MR; Iranmanesh, M | 1 |
| Babaie, M; Mendi, FD; Saljooghi, AS; Saljooghi, ZS; Zahmati, M | 1 |
| Amini, M; Atyabi, F; Dinarvand, R; Kamalinia, G; Khodagholi, F; Shaerzadeh, F; Sharifzadeh, M | 1 |
| Bayer, A; French, SW; Gebremariam, T; Ibrahim, AS; Lee, H; Luo, G; Spellberg, B; Xiong, YQ | 1 |
| Bridle, KR; Campbell, CM; Clouston, AD; Crawford, DH; de Guzman, CE; Jaskowski, L; Santrampurwala, N; Sobbe, A; Subramaniam, VN | 1 |
| Albert, ND; Kontoyiannis, DP; Lewis, RE | 1 |
| Alves, SH; Ferreiro, L; Jesus, FP; Pilotto, MB; Pötter, L; Santurio, JM; Weiblen, C; Zanette, RA | 1 |
| Chattipakorn, N; Chattipakorn, SC; Krintratun, W; Sripetchwandee, J; Wongjaikam, S | 1 |
| Brewer, C; Gonzalez, I; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
| Allegrini, PR; Fozard, L; Junker, U; Nick, H; Niederkofler, V; O'Reilly, T; Rojkjaer, L; Salie, R | 1 |
| Fatemi, SJ; Saljooghi, ASh | 1 |
| Al-Rousan, RM; Blough, ER; Katta, A; Laurino, J; Rice, KM; Triest, WE; Walker, EM; Wu, M | 1 |
| Aguilar, MI; Gonzalez, I; Moats, R; Nelson, M; Nick, H; Otto-Duessel, M; Shimada, H; Wood, JC | 1 |
| Aguilar, M; Moats, R; Nick, H; Otto-Duessel, M; Wood, JC | 1 |
24 other study(ies) available for deferasirox and Disease Models, Animal
| Article | Year |
|---|---|
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
Topics: Animals; Antiviral Agents; Artificial Intelligence; Chlorocebus aethiops; Disease Models, Animal; Drug Evaluation, Preclinical; High-Throughput Screening Assays; Immunocompetence; Inhibitory Concentration 50; Methacycline; Mice, Inbred C57BL; Protease Inhibitors; Quantitative Structure-Activity Relationship; Small Molecule Libraries; Vero Cells; Zika Virus; Zika Virus Infection | 2020 |
Effects of Deferasirox in Alzheimer's Disease and Tauopathy Animal Models.
Topics: Alzheimer Disease; Animals; Deferasirox; Deferoxamine; Disease Models, Animal; Humans; Iron; Iron Chelating Agents; Mice; Mice, Transgenic; tau Proteins; Tauopathies | 2022 |
Deferasirox alleviates DSS-induced ulcerative colitis in mice by inhibiting ferroptosis and improving intestinal microbiota.
Topics: Animals; Colitis; Colitis, Ulcerative; Colon; Deferasirox; Dextran Sulfate; Disease Models, Animal; Ferroptosis; Gastrointestinal Microbiome; Iron; Mice; Mice, Inbred C57BL; RNA, Ribosomal, 16S; Sodium Chloride; Sodium Chloride, Dietary | 2023 |
Deferasirox, a trivalent iron chelator, ameliorates neuronal damage in hemorrhagic stroke models.
Topics: Animals; Antioxidants; Apoptosis; Autophagy; Brain; Cell Death; Cell Line, Tumor; Deferasirox; Disease Models, Animal; Hemorrhagic Stroke; Humans; Iron; Iron Chelating Agents; Male; Mice; Neurons; Neuroprotective Agents; Reactive Oxygen Species | 2021 |
Therapeutic Effects of Iron Chelation in Atorvastatin-Induced Intracranial Hemorrhage of Zebrafish Larvae.
Topics: Animals; Animals, Genetically Modified; Apoptosis; Atorvastatin; Brain; Deferasirox; Disease Models, Animal; Dose-Response Relationship, Drug; Intracranial Hemorrhages; Iron Chelating Agents; Larva; Time Factors; Zebrafish | 2020 |
Deferasirox, an Iron-Chelating Agent, Improves Testicular Morphometric and Sperm Functional Parameters in a Rat Model of Varicocele.
Topics: Animals; Deferasirox; Disease Models, Animal; Humans; Iron Chelating Agents; Male; Rats; Rats, Wistar; Sperm Motility; Testis; Varicocele | 2021 |
Protective effects of deferasirox and N-acetyl-L-cysteine on iron overload-injured bone marrow.
Topics: Acetylcysteine; Animals; Benzoates; Colony-Forming Units Assay; Deferasirox; Disease Models, Animal; Flow Cytometry; Free Radical Scavengers; Hematopoiesis; Hematopoietic Stem Cells; Iron Chelating Agents; Iron Overload; Male; Mice, Inbred C57BL; Protective Agents; Reactive Oxygen Species; Reference Values; Reproducibility of Results; Time Factors; Treatment Outcome; Triazoles | 2017 |
Comparison of the effects of deferasirox, deferoxamine, and combination of deferasirox and deferoxamine on an aplastic anemia mouse model complicated with iron overload.
Topics: Anemia, Aplastic; Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Female; Iron Chelating Agents; Iron Overload; Mice; Mice, Inbred BALB C; Mice, Inbred DBA; Triazoles | 2018 |
Systemic iron chelation results in limited functional and histological recovery after traumatic spinal cord injury in rats.
Topics: Animals; Benzoates; Cervical Vertebrae; Deferasirox; Disease Models, Animal; Female; Iron Chelating Agents; Motor Activity; Rats; Rats, Sprague-Dawley; Recovery of Function; Spinal Cord; Spinal Cord Injuries; Triazoles | 2013 |
Gadolinium-deferasirox-D-glucosamine: novel anti-tumor and MR molecular (theranostic) imaging agent.
Topics: Animals; Antineoplastic Agents; Benzoates; Cell Line, Tumor; Chromatography, Thin Layer; Contrast Media; Deferasirox; Disease Models, Animal; Gadolinium; Glucosamine; Glucose; Hexokinase; Humans; Magnetic Resonance Imaging; Mice, Nude; Microscopy, Fluorescence; Neoplasms; Phosphorylation; Radionuclide Imaging; Radiopharmaceuticals; Rats; Time Factors; Triazoles; Tumor Necrosis Factor-alpha | 2013 |
Treatment of mercury vapor toxicity by combining deferasirox and deferiprone in rats.
Topics: Animals; Benzoates; Chelating Agents; Deferasirox; Deferiprone; Disease Models, Animal; Drug Therapy, Combination; Male; Mercury; Molecular Structure; Pyridones; Rats; Rats, Wistar; Tissue Distribution; Triazoles; Volatilization | 2013 |
Chelation of thallium by combining deferasirox and desferrioxamine in rats.
Topics: Animals; Benzoates; Chelation Therapy; Deferasirox; Deferoxamine; Disease Models, Animal; Dose-Response Relationship, Drug; Iron; Iron Chelating Agents; Male; Rats; Rats, Wistar; Spectrophotometry, Atomic; Thallium; Triazoles | 2016 |
Enhanced brain delivery of deferasirox-lactoferrin conjugates for iron chelation therapy in neurodegenerative disorders: in vitro and in vivo studies.
Topics: Alzheimer Disease; Animals; Apoptosis; Apoptosis Regulatory Proteins; Benzoates; Brain; Carbodiimides; Cell Line, Tumor; Chelating Agents; Chelation Therapy; Deferasirox; Disease Models, Animal; Drug Delivery Systems; Iron; Lactoferrin; Male; Nanostructures; Neurodegenerative Diseases; Neuroprotective Agents; PC12 Cells; Permeability; Rats; Rats, Wistar; Transcytosis; Triazoles | 2013 |
Combination therapy with iron chelation and vancomycin in treating murine staphylococcemia.
Topics: Animals; Anti-Bacterial Agents; Bacteremia; Bacterial Load; Benzoates; Chelating Agents; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Iron; Kidney; Methicillin-Resistant Staphylococcus aureus; Mice, Inbred BALB C; Microbial Sensitivity Tests; Microbial Viability; Severity of Illness Index; Spleen; Staphylococcal Infections; Treatment Outcome; Triazoles; Vancomycin | 2014 |
Inconsistent hepatic antifibrotic effects with the iron chelator deferasirox.
Topics: Actins; Administration, Oral; Animals; Benzoates; Cells, Cultured; Deferasirox; Disease Models, Animal; Gene Expression; Hepatic Stellate Cells; Humans; Iron Chelating Agents; Liver; Liver Cirrhosis; Male; Matrix Metalloproteinase 2; Mice; Mice, Transgenic; Procollagen; Triazoles | 2015 |
Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis.
Topics: Amphotericin B; Animals; Antifungal Agents; Area Under Curve; Aspergillosis; Aspergillus fumigatus; Benzoates; Caspofungin; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Invasive Pulmonary Aspergillosis; Lipopeptides; Lung; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mucormycosis; Neutropenia; Rhizopus; Treatment Outcome; Triazoles | 2014 |
Micafungin alone and in combination therapy with deferasirox against Pythium insidiosum.
Topics: Animals; Antifungal Agents; Benzoates; Deferasirox; Disease Models, Animal; Drug Therapy, Combination; Echinocandins; Female; Horse Diseases; Horses; Lipopeptides; Micafungin; Microbial Sensitivity Tests; Pythiosis; Pythium; Rabbits; Triazoles | 2015 |
A combination of an iron chelator with an antioxidant effectively diminishes the dendritic loss, tau-hyperphosphorylation, amyloids-β accumulation and brain mitochondrial dynamic disruption in rats with chronic iron-overload.
Topics: Acetylcysteine; Amyloid beta-Peptides; Animals; Antioxidants; Apoptosis; Benzoates; Brain; Deferasirox; Deferoxamine; Dendrites; Diet; Disease Models, Animal; Drug Therapy, Combination; Iron; Iron Chelating Agents; Iron Overload; Male; Mitochondrial Dynamics; Neurodegenerative Diseases; Phosphorylation; Random Allocation; Rats, Wistar; tau Proteins; Triazoles | 2016 |
Safety and efficacy of combined chelation therapy with deferasirox and deferoxamine in a gerbil model of iron overload.
Topics: Animals; Benzoates; Deferasirox; Deferoxamine; Disease Models, Animal; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Gerbillinae; Heart; Iron Overload; Liver; Organ Size; Treatment Outcome; Triazoles | 2008 |
Deferasirox reduces iron overload in a murine model of juvenile hemochromatosis.
Topics: Animals; Benzoates; Deferasirox; Disease Models, Animal; Drug Evaluation, Preclinical; GPI-Linked Proteins; Hemochromatosis; Hemochromatosis Protein; Humans; Iron; Iron Chelating Agents; Magnetic Resonance Imaging; Membrane Proteins; Mice; Mice, Knockout; Organ Specificity; Triazoles | 2009 |
Removal of thallium by deferasirox in rats as biological model.
Topics: Animals; Benzoates; Body Weight; Chelating Agents; Chelation Therapy; Deferasirox; Disease Models, Animal; Dose-Response Relationship, Drug; Heavy Metal Poisoning; Iron; Male; Metals, Heavy; Poisoning; Random Allocation; Rats; Rats, Wistar; Spectrophotometry, Atomic; Thallium; Triazoles | 2011 |
Deferasirox protects against iron-induced hepatic injury in Mongolian gerbil.
Topics: Animals; Apoptosis; bcl-2-Associated X Protein; Benzoates; Caspase 3; Chemical and Drug Induced Liver Injury; Deferasirox; Disease Models, Animal; DNA Fragmentation; Ferritins; Gerbillinae; Iron Chelating Agents; Iron Overload; Iron-Dextran Complex; Male; Proto-Oncogene Proteins c-bcl-2; Reactive Oxygen Species; Translational Research, Biomedical; Triazoles | 2011 |
Deferasirox and deferiprone remove cardiac iron in the iron-overloaded gerbil.
Topics: Animals; Benzoates; Deferasirox; Deferiprone; Disease Models, Animal; Female; Gerbillinae; Heart; Iron; Iron Chelating Agents; Iron Overload; Liver; Organ Size; Pyridones; Triazoles | 2006 |
Comparison of twice-daily vs once-daily deferasirox dosing in a gerbil model of iron cardiomyopathy.
Topics: Animals; Benzoates; Cardiomyopathies; Deferasirox; Disease Models, Animal; Drug Administration Schedule; Female; Gerbillinae; Iron; Iron Chelating Agents; Iron Overload; Liver; Myocardium; Triazoles | 2007 |